Zacks: Brokerages Anticipate Kadmon Co. (KDMN) Will Post Quarterly Sales of $2.67 Million

Brokerages predict that Kadmon Co. (NYSE:KDMN) will post sales of $2.67 million for the current quarter, Zacks reports. Three analysts have provided estimates for Kadmon’s earnings, with the highest sales estimate coming in at $3.46 million and the lowest estimate coming in at $1.45 million. Kadmon posted sales of $5.57 million during the same quarter last year, which suggests a negative year over year growth rate of 52.1%. The business is scheduled to issue its next quarterly earnings results on Monday, May 21st.

According to Zacks, analysts expect that Kadmon will report full-year sales of $9.94 million for the current year, with estimates ranging from $5.50 million to $16.70 million. For the next year, analysts forecast that the firm will post sales of $47.92 million per share, with estimates ranging from $5.60 million to $117.36 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Kadmon.

How to Become a New Pot Stock Millionaire

Kadmon (NYSE:KDMN) last posted its quarterly earnings results on Tuesday, March 6th. The company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.12. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the previous year, the company earned ($0.50) earnings per share. The company’s revenue for the quarter was down 65.1% compared to the same quarter last year.

KDMN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Friday, January 12th. Jefferies Group upped their price target on Kadmon to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 13th. Piper Jaffray restated a “positive” rating and issued a $9.00 price target (up from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Kadmon in a research note on Friday, March 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $11.45.

KDMN stock traded down $0.08 during midday trading on Monday, hitting $4.25. The company’s stock had a trading volume of 178,597 shares, compared to its average volume of 907,608. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.86. The company has a market capitalization of $340.52, a price-to-earnings ratio of -2.99 and a beta of 3.90.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sawtooth Solutions LLC bought a new position in shares of Kadmon during the 4th quarter valued at approximately $799,000. Goldentree Asset Management LP boosted its position in shares of Kadmon by 673.6% during the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock valued at $5,834,000 after acquiring an additional 1,403,397 shares during the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Kadmon during the 4th quarter valued at approximately $241,000. Geode Capital Management LLC boosted its position in shares of Kadmon by 172.4% during the 4th quarter. Geode Capital Management LLC now owns 463,844 shares of the company’s stock valued at $1,679,000 after acquiring an additional 293,569 shares during the last quarter. Finally, Spark Investment Management LLC bought a new position in shares of Kadmon during the 4th quarter valued at approximately $868,000. Hedge funds and other institutional investors own 61.71% of the company’s stock.

WARNING: “Zacks: Brokerages Anticipate Kadmon Co. (KDMN) Will Post Quarterly Sales of $2.67 Million” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2018/04/17/zacks-brokerages-anticipate-kadmon-co-kdmn-will-post-quarterly-sales-of-2-67-million.html.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply